RxDoctor Payments Data

William Lamar, MD

Nephrology · Mobile, ALNPI 1073599601

Payments from drug & device makers

$3,179in general payments, 2019–2025

Across 171 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$368
  • Otsuka America Pharmaceutical, Inc.$238
  • Novartis$204
  • Travere Therapeutics, Inc.$173
  • Akebia Therapeutics Inc$163
  • plus $723 from 16 others

What the payments were for

  • Food & beverage$3,16099%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,179 in reported general payments places this provider in the 50th percentile of 164 nephrology providers in Alabama.

See all nephrology providers in Alabama

Medicare billing

Part B allowed, 2024
$154,383
Medicare patients
334
Services billed
1,582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan11$221,920
FarxigaDapagliflozin Propanediol205$166,292
AuryxiaFerric Citrate50$126,980
JardianceEmpagliflozin107$124,698
Thiola EcTiopronin12$91,001
VelphoroSucroferric Oxyhydroxide20$67,097
Sevelamer Carbonate53$25,617
OzempicSemaglutide24$21,696
LokelmaSodium Zirconium Cyclosilicate25$17,703
JanuviaSitagliptin Phosphate21$16,074
MyrbetriqMirabegron24$11,610
KerendiaFinerenone12$9,368
Potassium Citrate ErPotassium Citrate22$4,006
Calcium Acetate26$2,990
Clonidine15$2,402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$238$221,92011 claims
AstraZenecaFarxiga, Lokelma$368$183,995230 claims
Akebia Therapeutics IncAuryxia$163$126,98050 claims
Novo NordiskOzempic$15$21,69624 claims
BayerKerendia$59$9,36812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 164 nephrology providers in Alabama.

Other nephrology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →